{"id":86075,"date":"2026-03-31T17:33:11","date_gmt":"2026-03-31T15:33:11","guid":{"rendered":"https:\/\/gulftech-news.com\/en\/?p=86075"},"modified":"2026-03-31T17:33:12","modified_gmt":"2026-03-31T15:33:12","slug":"novo-nordisk-a-s-wegovy-hd-semaglutide-7-2-mg-approved-in-the-us-providing-20-7-mean-weight-loss","status":"publish","type":"post","link":"https:\/\/gulftech-news.com\/en\/2026\/03\/31\/novo-nordisk-a-s-wegovy-hd-semaglutide-7-2-mg-approved-in-the-us-providing-20-7-mean-weight-loss\/","title":{"rendered":"Novo Nordisk A\/S: Wegovy\u00ae\ufe0f HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss"},"content":{"rendered":"\n<pre class=\"wp-block-code\"><code><a href=\"https:\/\/www.wegovy.com\/\">Wegovy<\/a>\u00ae\ufe0f HD demonstrated a mean weight loss of 20.7%1, and around one-third of patients achieved 25% or greater weight loss in the STEP UP trial\nFirst US FDA approval of a GLP-1 treatment under the Commissioner\u2019s National Priority Voucher pilot programme, for products addressing critical US national health priorities\nWegovy\u00ae\ufe0f HD complements Wegovy\u00ae\ufe0f 2.4 mg, which is already approved in the US for weight management and cardiovascular risk reduction\nNovo Nordisk expects to launch Wegovy\u00ae\ufe0f HD in the US in April 2026<\/code><\/pre>\n\n\n\n<p>Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Wegovy\u00ae\ufe0f HD (once-weekly injectable semaglutide 7.2 mg) to reduce excess body weight and maintain weight reduction long-term. The FDA awarded a Commissioner\u2019s National Priority Voucher for Wegovy\u00ae\ufe0f HD, accelerating its review and underscoring its potential to address critical patient needs and national health priorities in the US.<\/p>\n\n\n\n<p><br>The accelerated approval is based on results from the STEP UP trial programme. In the STEP UP trial, semaglutide 7.2 mg injected once weekly demonstrated 20.7%1 mean weight loss in participants with obesity, and approximately one in three people experienced 25% or greater weight loss. In the STEP UP type 2 diabetes (T2D) trial, in participants with obesity and type 2 diabetes, semaglutide 7.2 mg demonstrated a mean weight loss of 14.1%1. In both trials, the well-known safety and tolerability profile of semaglutide was reaffirmed with semaglutide 7.2 mg, which was comparable to previous trials with semaglutide for weight management.<\/p>\n\n\n\n<p><br>\u201cSince its launch in 2021, Wegovy\u00ae\ufe0f has transformed the lives of many people living with obesity and helped them achieve meaningful weight loss and important cardiometabolic benefits, including an unprecedented reduction in cardiovascular risk,\u201d said Mike Doustdar, president and CEO of Novo Nordisk. \u201cEarlier this year, we launched the Wegovy\u00ae\ufe0f pill, and with the accelerated approval of Wegovy\u00ae\ufe0f HD, we are introducing a new offering for our injectable semaglutide that provides even greater weight loss of approximately 21%. At Novo Nordisk, our goal is to provide innovative therapies that support healthier lives for people living with obesity, and we look forward to launching Wegovy\u00ae\ufe0f HD to help even more people reach their weight and health goals.\u201d<\/p>\n\n\n\n<p><br>Novo Nordisk expects to launch Wegovy\u00ae\ufe0f HD in a single-dose pen in the US in April 2026.<br>Wegovy\u00ae\ufe0f 7.2 mg is already approved for adults with obesity in the EU and the UK. Novo Nordisk expects regulatory decisions in the EU and the UK on semaglutide 7.2 mg in a single-dose pen in the second half of 2026<\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Wegovy\u00ae\ufe0f HD demonstrated a mean weight loss of 20.7%1, and around one-third of patients achieved 25% or greater weight loss in the STEP UP trial First US FDA approval of a GLP-1 treatment under the Commissioner\u2019s National Priority Voucher pilot programme, for products addressing critical US national health priorities Wegovy\u00ae\ufe0f HD complements Wegovy\u00ae\ufe0f 2.4 mg, &hellip;<\/p>\n","protected":false},"author":1,"featured_media":86076,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[439],"tags":[4848],"class_list":["post-86075","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-research-universities","tag-wegovy"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>novo-nordisk-a-s-wegovy-hd-semaglutide-7-2-mg-approved<\/title>\n<meta name=\"description\" content=\"Wegovy\u00ae\ufe0f HD demonstrated a mean weight loss of 20.7%1, and around one-third of patients achieved 25% or greater weight\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/gulftech-news.com\/en\/2026\/03\/31\/novo-nordisk-a-s-wegovy-hd-semaglutide-7-2-mg-approved-in-the-us-providing-20-7-mean-weight-loss\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"novo-nordisk-a-s-wegovy-hd-semaglutide-7-2-mg-approved\" \/>\n<meta property=\"og:description\" content=\"Wegovy\u00ae\ufe0f HD demonstrated a mean weight loss of 20.7%1, and around one-third of patients achieved 25% or greater weight\" \/>\n<meta property=\"og:url\" content=\"https:\/\/gulftech-news.com\/en\/2026\/03\/31\/novo-nordisk-a-s-wegovy-hd-semaglutide-7-2-mg-approved-in-the-us-providing-20-7-mean-weight-loss\/\" \/>\n<meta property=\"og:site_name\" content=\"Gulf Tech News\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-31T15:33:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-31T15:33:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/gulftech-news.com\/en\/wp-content\/uploads\/2026\/03\/WhatsApp-Image-2026-03-31-at-17.12.06.jpeg?v=1774970528\" \/>\n\t<meta property=\"og:image:width\" content=\"1191\" \/>\n\t<meta property=\"og:image:height\" content=\"909\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/gulftech-news.com\/en\/2026\/03\/31\/novo-nordisk-a-s-wegovy-hd-semaglutide-7-2-mg-approved-in-the-us-providing-20-7-mean-weight-loss\/\",\"url\":\"https:\/\/gulftech-news.com\/en\/2026\/03\/31\/novo-nordisk-a-s-wegovy-hd-semaglutide-7-2-mg-approved-in-the-us-providing-20-7-mean-weight-loss\/\",\"name\":\"novo-nordisk-a-s-wegovy-hd-semaglutide-7-2-mg-approved\",\"isPartOf\":{\"@id\":\"https:\/\/gulftech-news.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/gulftech-news.com\/en\/2026\/03\/31\/novo-nordisk-a-s-wegovy-hd-semaglutide-7-2-mg-approved-in-the-us-providing-20-7-mean-weight-loss\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/gulftech-news.com\/en\/2026\/03\/31\/novo-nordisk-a-s-wegovy-hd-semaglutide-7-2-mg-approved-in-the-us-providing-20-7-mean-weight-loss\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/gulftech-news.com\/en\/wp-content\/uploads\/2026\/03\/WhatsApp-Image-2026-03-31-at-17.12.06.jpeg?v=1774970528\",\"datePublished\":\"2026-03-31T15:33:11+00:00\",\"dateModified\":\"2026-03-31T15:33:12+00:00\",\"author\":{\"@id\":\"https:\/\/gulftech-news.com\/en\/#\/schema\/person\/fe4fb4a528850de8e0c9209ece797e29\"},\"description\":\"Wegovy\u00ae\ufe0f HD demonstrated a mean weight loss of 20.7%1, and around one-third of patients achieved 25% or greater weight\",\"breadcrumb\":{\"@id\":\"https:\/\/gulftech-news.com\/en\/2026\/03\/31\/novo-nordisk-a-s-wegovy-hd-semaglutide-7-2-mg-approved-in-the-us-providing-20-7-mean-weight-loss\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/gulftech-news.com\/en\/2026\/03\/31\/novo-nordisk-a-s-wegovy-hd-semaglutide-7-2-mg-approved-in-the-us-providing-20-7-mean-weight-loss\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/gulftech-news.com\/en\/2026\/03\/31\/novo-nordisk-a-s-wegovy-hd-semaglutide-7-2-mg-approved-in-the-us-providing-20-7-mean-weight-loss\/#primaryimage\",\"url\":\"https:\/\/gulftech-news.com\/en\/wp-content\/uploads\/2026\/03\/WhatsApp-Image-2026-03-31-at-17.12.06.jpeg?v=1774970528\",\"contentUrl\":\"https:\/\/gulftech-news.com\/en\/wp-content\/uploads\/2026\/03\/WhatsApp-Image-2026-03-31-at-17.12.06.jpeg?v=1774970528\",\"width\":1191,\"height\":909},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/gulftech-news.com\/en\/2026\/03\/31\/novo-nordisk-a-s-wegovy-hd-semaglutide-7-2-mg-approved-in-the-us-providing-20-7-mean-weight-loss\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/gulftech-news.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo Nordisk A\/S: Wegovy\u00ae\ufe0f HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/gulftech-news.com\/en\/#website\",\"url\":\"https:\/\/gulftech-news.com\/en\/\",\"name\":\"Gulf Tech News\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/gulftech-news.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/gulftech-news.com\/en\/#\/schema\/person\/fe4fb4a528850de8e0c9209ece797e29\",\"name\":\"Admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/gulftech-news.com\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/3d0f856a1e2ecd3d5d413e0d92ad06cc1e8a8204ee82b45b90080aea490467d8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/3d0f856a1e2ecd3d5d413e0d92ad06cc1e8a8204ee82b45b90080aea490467d8?s=96&d=mm&r=g\",\"caption\":\"Admin\"},\"sameAs\":[\"https:\/\/gulftech-news.com\/en\"],\"url\":\"https:\/\/gulftech-news.com\/en\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"novo-nordisk-a-s-wegovy-hd-semaglutide-7-2-mg-approved","description":"Wegovy\u00ae\ufe0f HD demonstrated a mean weight loss of 20.7%1, and around one-third of patients achieved 25% or greater weight","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/gulftech-news.com\/en\/2026\/03\/31\/novo-nordisk-a-s-wegovy-hd-semaglutide-7-2-mg-approved-in-the-us-providing-20-7-mean-weight-loss\/","og_locale":"en_US","og_type":"article","og_title":"novo-nordisk-a-s-wegovy-hd-semaglutide-7-2-mg-approved","og_description":"Wegovy\u00ae\ufe0f HD demonstrated a mean weight loss of 20.7%1, and around one-third of patients achieved 25% or greater weight","og_url":"https:\/\/gulftech-news.com\/en\/2026\/03\/31\/novo-nordisk-a-s-wegovy-hd-semaglutide-7-2-mg-approved-in-the-us-providing-20-7-mean-weight-loss\/","og_site_name":"Gulf Tech News","article_published_time":"2026-03-31T15:33:11+00:00","article_modified_time":"2026-03-31T15:33:12+00:00","og_image":[{"width":1191,"height":909,"url":"https:\/\/gulftech-news.com\/en\/wp-content\/uploads\/2026\/03\/WhatsApp-Image-2026-03-31-at-17.12.06.jpeg?v=1774970528","type":"image\/jpeg"}],"author":"Admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Admin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/gulftech-news.com\/en\/2026\/03\/31\/novo-nordisk-a-s-wegovy-hd-semaglutide-7-2-mg-approved-in-the-us-providing-20-7-mean-weight-loss\/","url":"https:\/\/gulftech-news.com\/en\/2026\/03\/31\/novo-nordisk-a-s-wegovy-hd-semaglutide-7-2-mg-approved-in-the-us-providing-20-7-mean-weight-loss\/","name":"novo-nordisk-a-s-wegovy-hd-semaglutide-7-2-mg-approved","isPartOf":{"@id":"https:\/\/gulftech-news.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/gulftech-news.com\/en\/2026\/03\/31\/novo-nordisk-a-s-wegovy-hd-semaglutide-7-2-mg-approved-in-the-us-providing-20-7-mean-weight-loss\/#primaryimage"},"image":{"@id":"https:\/\/gulftech-news.com\/en\/2026\/03\/31\/novo-nordisk-a-s-wegovy-hd-semaglutide-7-2-mg-approved-in-the-us-providing-20-7-mean-weight-loss\/#primaryimage"},"thumbnailUrl":"https:\/\/gulftech-news.com\/en\/wp-content\/uploads\/2026\/03\/WhatsApp-Image-2026-03-31-at-17.12.06.jpeg?v=1774970528","datePublished":"2026-03-31T15:33:11+00:00","dateModified":"2026-03-31T15:33:12+00:00","author":{"@id":"https:\/\/gulftech-news.com\/en\/#\/schema\/person\/fe4fb4a528850de8e0c9209ece797e29"},"description":"Wegovy\u00ae\ufe0f HD demonstrated a mean weight loss of 20.7%1, and around one-third of patients achieved 25% or greater weight","breadcrumb":{"@id":"https:\/\/gulftech-news.com\/en\/2026\/03\/31\/novo-nordisk-a-s-wegovy-hd-semaglutide-7-2-mg-approved-in-the-us-providing-20-7-mean-weight-loss\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/gulftech-news.com\/en\/2026\/03\/31\/novo-nordisk-a-s-wegovy-hd-semaglutide-7-2-mg-approved-in-the-us-providing-20-7-mean-weight-loss\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/gulftech-news.com\/en\/2026\/03\/31\/novo-nordisk-a-s-wegovy-hd-semaglutide-7-2-mg-approved-in-the-us-providing-20-7-mean-weight-loss\/#primaryimage","url":"https:\/\/gulftech-news.com\/en\/wp-content\/uploads\/2026\/03\/WhatsApp-Image-2026-03-31-at-17.12.06.jpeg?v=1774970528","contentUrl":"https:\/\/gulftech-news.com\/en\/wp-content\/uploads\/2026\/03\/WhatsApp-Image-2026-03-31-at-17.12.06.jpeg?v=1774970528","width":1191,"height":909},{"@type":"BreadcrumbList","@id":"https:\/\/gulftech-news.com\/en\/2026\/03\/31\/novo-nordisk-a-s-wegovy-hd-semaglutide-7-2-mg-approved-in-the-us-providing-20-7-mean-weight-loss\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/gulftech-news.com\/en\/"},{"@type":"ListItem","position":2,"name":"Novo Nordisk A\/S: Wegovy\u00ae\ufe0f HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss"}]},{"@type":"WebSite","@id":"https:\/\/gulftech-news.com\/en\/#website","url":"https:\/\/gulftech-news.com\/en\/","name":"Gulf Tech News","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/gulftech-news.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/gulftech-news.com\/en\/#\/schema\/person\/fe4fb4a528850de8e0c9209ece797e29","name":"Admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/gulftech-news.com\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/3d0f856a1e2ecd3d5d413e0d92ad06cc1e8a8204ee82b45b90080aea490467d8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3d0f856a1e2ecd3d5d413e0d92ad06cc1e8a8204ee82b45b90080aea490467d8?s=96&d=mm&r=g","caption":"Admin"},"sameAs":["https:\/\/gulftech-news.com\/en"],"url":"https:\/\/gulftech-news.com\/en\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/gulftech-news.com\/en\/wp-json\/wp\/v2\/posts\/86075","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/gulftech-news.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/gulftech-news.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/gulftech-news.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/gulftech-news.com\/en\/wp-json\/wp\/v2\/comments?post=86075"}],"version-history":[{"count":1,"href":"https:\/\/gulftech-news.com\/en\/wp-json\/wp\/v2\/posts\/86075\/revisions"}],"predecessor-version":[{"id":86077,"href":"https:\/\/gulftech-news.com\/en\/wp-json\/wp\/v2\/posts\/86075\/revisions\/86077"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/gulftech-news.com\/en\/wp-json\/wp\/v2\/media\/86076"}],"wp:attachment":[{"href":"https:\/\/gulftech-news.com\/en\/wp-json\/wp\/v2\/media?parent=86075"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/gulftech-news.com\/en\/wp-json\/wp\/v2\/categories?post=86075"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/gulftech-news.com\/en\/wp-json\/wp\/v2\/tags?post=86075"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}